Supportive Care | Specialty

FDA Issues a Complete Response Letter for Eflapegrastim for Chemo-Induced Neutropenia

August 6th 2021

The FDA has issued a complete response letter to Spectrum Pharmaceuticals regarding the biologics license application for eflapegrastimas a potential option for the management of chemotherapy-induced neutropenia.

ACCC Tool Gives Individualized Guidance for Geriatric Assessment Implementation in Patients With Cancer

June 2nd 2021

Melissa (Kah Poh) Loh, BMedSci, MBBCh, BAO, discusses the challenges of utilizing geriatric assessment in oncology and steps that the ACCC resources can provide to institutions that want to incorporate geriatric assessment into practice.

FDA Grants Priority Review to Maribavir for Select Post-Transplant Recipients With CMV

May 21st 2021

The FDA has accepted a new drug application for maribavir for the treatment of post-transplant recipients with cytomegalovirus infection who are refractory and/or resistant to previous anti-CMV treatment.

Plinabulin/Pegfilgrastim Combo Reduces Rate of Chemotherapy-Induced Neutropenia

November 16th 2020

November 16, 2020 - The combination of plinabulin and pegfilgrastim showed a statistically significant improvement in the rate of prevention of grade 4 neutropenia versus pegfilgrastim alone in patients with cancer undergoing chemotherapy.

Trilaciclib Reduces Need for G-CSF, RBC Transfusions From Chemo-Induced AEs in ES-SCLC

October 19th 2020

Treatment with the CDK4/6 inhibitor trilaciclib prior to chemotherapy compared with placebo significantly reduced the need for supportive care interventions in the management of severe neutropenia and grade 3/4 anemia induced by chemotherapy in patients with extensive-stage small cell lung cancer.

Avatrombopag Falls Short in Chemotherapy-Induced Thrombocytopenia

October 9th 2020

Avatrombopag failed to meet the composite primary end point of avoiding platelet transfusions, chemotherapy dose reductions by 15% or greater, and chemotherapy dose delays by 4 days or more in patients with solid tumors and chemotherapy-induced thrombocytopenia.

Managing High-Dose Methotrexate Toxicity

October 1st 2020

Smith-Stanley Shares Strategies to Address Gender Disparities in Oncology

September 30th 2020

To address disparities, it is important for institutions to embrace and promote the fostering of an inclusive culture and environment for healthcare professionals of all races and genders, and to adequately equip women specifically with the tools they need to achieve success in the field.

Plinabulin Shows Efficacy in Chemo-Induced Neutropenia Prevention During COVID-19 Era

September 29th 2020

Plinabulin was found to be a more favorable option for the prevention of chemotherapy-induced neutropenia compared with pegfilgrastim during the coronavirus disease 2019 pandemic.

From the Ophthalmologist’s Eye: Managing Ocular Toxicities With Belantamab Mafodotin in Myeloma

September 25th 2020

Shaily Shah, MD, discusses disease and treatment-related ocular toxicities that can arise in patients with cancer, specific management strategies for patients receiving belantamab mafodotin who develop ocular toxicities, and the importance of collaborative management of these patients.

FDA Grants Breakthrough Therapy Designation to Plinabulin for Chemotherapy-Induced Neutropenia

September 10th 2020

The FDA has granted a breakthrough therapy designation to plinabulin for chemotherapy-induced neutropenia.

Practices Adopt Strategies for Tackling Disparities in Cancer Care

September 6th 2020

One of the main methods to address this disparity of cancer care is using community health workers and navigators to do the grassroots outreach.

Dr. Greenlee on Mitigating the Risk of Cardiovascular Disease in Breast Cancer

August 31st 2020

Heather Greenlee, ND, PhD, MPH, provides strategies to mitigate the increased risk of cardiovascular disease in women with breast cancer.

Dr. Reid on Remaining Challenges Regarding the Management of Immune-Related AEs

August 21st 2020

Pankti Reid, MD, MPH, discusses remaining challenges regarding the management of immune-related adverse effects.

Navigating Immune-Related Adverse Effects in Oncology

August 12th 2020

Marianne Davies, DNP, MSN, RN, APRN, CNS-BC, ACNP-BC, AOCNP, discusses the management of immune-related adverse effects in patients who are receiving treatment with checkpoint inhibitors.

Dizon Discusses Elements of Sexual Health in Gynecologic Cancer

August 6th 2020

In our exclusive interview, Don S. Dizon, MD, FACP, FASCO, discusses the primary physical and residual psychological effects of gynecologic cancers on women’s sexual health, the challenges of broaching these topics in the clinic, and the role oncologists play in helping patients manage these difficulties.

Managing Systemic Toxicities and Limiting Therapy Non-Adherence in Breast Cancer

July 31st 2020

One of the most important tasks that oncology nurses face is ensuring that patients are taking their medications consistently and correctly, and that adverse events are properly managed—specifically in those patients with breast cancer.

Oral Oncolytics Will Require Health Care System to Adapt

July 21st 2020

Judging from the drug pipeline, the future of oncology is oral chemotherapy.

SHAWL Study: A Sexual Health Assessment in Women With Lung Cancer

July 10th 2020

Data suggest that up to 95% of patients with lung cancer score below the fiftieth percentile on sexual function during and after completion of cancer-directed therapy.

F-627 Shows Strong, Durable Benefit in Chemotherapy-Induced Neutropenia in Breast Cancer

July 9th 2020

Efbemalenograstim alpha (F-627) has demonstrated strong and lasting benefit when used as a treatment for chemotherapy-induced neutropenia in patients with breast cancer, meeting the primary and secondary end points of a phase 3 study.